Safety & Efficacy of Qurs e Fishar in Mild to Moderate Hypertensive Patients in Pakistan

Recruiting now · Phase 3

Conditions studied: Hypertension

In brief

The herbal medicine Qurs-e-Fishar to treat mild to moderate High blood pressure or hypertension comprises of Rauwolfia serpentina. A product of Hamdard Laboratories (Waqf) Pakistan. A Phase III Safety \& Efficacy Open-label, Single-Arm, Interventional, Multicenter, Study in mild to moderate hypertensive, adults (30 to 60 years of age) prescribed with study product for 12 weeks (84 days). Primary End Points: 1. Reduction in diastolic blood pressure less than 130 / 80 mmHg at the end of the study period (accepted by WHO) or if there was a fall of 20 / 10 mmHg or more in diastolic blood pressure as compared to baseline. 2. Type, frequency and severity of ADRs during the study period. Secondary End Points: 1\. Compliance of the prescribed study medication.

Key facts

Study ID

NCT06852079

Run by

Abdul Bari

People needed

119

Starts

2023-12-23

Expected to finish

2025-12-31

Last updated by the study team

2025-02-28

Who can join

Age: 30 and older, up to 60. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Ability to sign ICD
• Participant(s) are willing and able to fulfill the requirements of the study protocol
• Mild to moderate hypertensive
• Mild hypertension range (140-159/90-99 mm Hg)
• Moderate hypertension range (160-179/100-109 mm Hg)
• Be between the age of 30 to 60 year

You may not qualify if…

• Patients with recent history of following will be excluded:
• Severe hypertension,
• Congestive cardiac failure,
• Left ventricular failure,
• Myocardial ischemia,
• Renal failure or
• Cerebrovascular accidents

Where it is running

• Taj Medical Complex, Hamdard University Hospital — Karachi, Sindh, Pakistan (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.